- Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial.Ann Intern Med. 2016; 165: 609-616
- Duodenal infusion of donor feces for recurrent Clostridium difficile.N Engl J Med. 2013; 368: 407-415
- Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook.Gastroenterology. 2015; 149: 223-237
- Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies.Clin Gastroenterol Hepatol. 2014; 12: 283-288
Food and Drug Administration (FDA). Public workshop: Fecal microbiota for transplantation. 2013; Available: www.fda.gov/biologicsbloodvaccines/newsevents/workshopsmeetingsconferences/ucm341643.htm. Accessed September 26, 2016.
Food and Drug Administration (FDA). Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. 2013; Available: www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM361393.pdf.
- AGA's approach to the microbiome.Gastroenterology. 2014; 146: 1119-1121
American Gastroenterological Association (AGA). Clinical research studies. Available: www.gastro.org/patient-care/clinical-research-trials. Accessed September 26, 2016.
- Long-term Follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience.J Clin Gastroenterol. 2016; 50: 398-402
- Fatal aspiration pneumonia as a complication of fecal microbiota transplant.Clin Infect Dis. 2015; 61: 136-137
- Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection.Clin Gastroenterol Hepatol. 2013; 11: 1036-1038
- Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.Am J Gastroenterol. 2014; 109: 1065-1071
Sinai AppLab. 2016; Available: http://sinaiapplab.org/.
- Turning participatory microbiome research into usable data: lessons from the American Gut Project.J Microbiol Biol Educ. 2016; 17: 46-50
- From stool transplants to next-generation microbiota therapeutics.Gastroenterology. 2014; 146: 1573-1582
Contributors include Ashish Atreja, Stacy A. Kahn, Rob Knight, James D. Lewis, Thomas A. Moore, and David T. Rubin. Participating institutions include the Warren Alpert Medical School of Brown University, Miriam Hospital, and Lifespan Hospital System, Providence, Rhode Island; American Gastroenterological Association Institute, Center for Gut Microbiome Research and Education, Bethesda, Maryland; Yale School of Medicine, New Haven, Connecticut; VA Connecticut Healthcare System, West Haven, Connecticut; University of Pennsylvania, Philadelphia, Pennsylvania; Mount Sinai School of Medicine, New York, New York; Boston Children’s Hospital, Boston, Massachusetts; University of California, San Diego, California; Infectious Disease Consultants (IDC) of Kansas, Wichita, Kansas; and the University of Chicago Medicine, Chicago, Illinois.
Conflicts of interest The authors have made the following disclosures: Colleen R. Kelly is a consultant and site investigator for Seres Health. She has received research support from Assembly Biosciences and acted as a consultant for Summit Therapeutics. Gary D. Wu has received research support from Seres Therapeutics, Intercept Pharmaceuticals, Takeda, and Nestle and served on the scientific advisory boards for Chr. Hansen and Janssen. The remaining authors disclose no conflicts.